Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
30 hedge funds and large institutions have $9.18M invested in Amplify Treatments, Testing and Advancements ETF in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
25% more funds holding
Funds holding: 24 → 30 (+6)
4% less capital invested
Capital invested by funds: $9.55M → $9.18M (-$372K)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$809K |
| 2 |
Jane Street
New York
|
+$211K |
| 3 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$51.4K |
| 4 |
CHC
City Holding Co
Charleston,
West Virginia
|
+$15K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$8.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$347K |
| 2 |
G
Gainplan
Bloomfield Hills,
Michigan
|
-$246K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$131K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$128K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$122K |
GERM Hedge Fund Activity: Q4 2021 in Review
30 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q4 2021, worth a combined $9.18M — down 3.9% from $9.55M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GERM positions and 3 closed out — a net gain of 6 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $809K. The largest seller was Citadel Advisors, exiting entirely with an estimated $347K sold.
- 30 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q4 2021, up from 24 in Q3 2021.
- Funds reported $9.18M of Amplify Treatments, Testing and Advancements ETF stock for Q4 2021, down 3.9% quarter-over-quarter.
- 9 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q4 2021 and 3 closed out, a net change of +6 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q4 2021 was Raymond James Financial Services Advisors, an estimated $809K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q4 2021 was Citadel Advisors, an estimated $347K sold.
Based on aggregated 13F filings for Q4 2021.